TO THE EDITOR
The t(9;22) translocation is identified in about 3-5% of children with acute lymphoblastic leukemia (ALL) 1, 2 and in about 25% of adult patients. 3 In both children and adults with ALL, the t(9;22) presence is associated with a high risk for treatment failure. 4, 5 However, recent retrospective studies showed that Ph þ childhood ALL is a heterogeneous disease with regard to treatment response. 1, 2, 5 High leukocyte count, old age and poor response to the prephase treatment with prednisone and intrathecal metotrexate influence treatment outcome. 1, 2, 5 Patients with prednisone good response (PGR) had a significantly lower risk of treatment failure compared to those with prednisone poor response (PPR), when treated with intensive Berlin-Frankfurt-Mü nster (BFM) chemotherapy, whether associated with bone marrow transplantation (BMT) or not.
1 PPR children present an equally poor clinical response and prognosis as Ph þ ALL adults. 6 Recent studies on gene expression profile in childhood and adult ALL 7, 8 distinguished gene signatures specific to genetic subclasses. However, Ph þ ALL showed the weakest signature among genetically distinct subclasses, indicating high heterogeneity, which correlates with the clinical variability.
In an attempt to dissect the heterogeneity in Ph þ acute leukemia, we studied the expression levels at diagnosis of a selected number of genes that had emerged as being particularly significant from the two Ph þ gene expression profile studies published so far. 7, 8 We limited the analysis to genes involved in cell cycle, apoptosis or stress response. Among the 10 genes whose expression was specific enough to discriminate childhood Ph þ leukemia from other genetic subclasses, 7 we selected four related genes: mitogen-activated protein-kinaseactivated protein kinase 3 (MAPKAPK3), Cyclin D2 (CCND2), caspase 8 (CASP8) and caspase 10 (CASP10). A further five genes: histone-deacetylase 2 (HDAC2), minichromosome maintenance, S. Pombe, homolog of 6 (MCM6), microtubule affinityregulating kinase 3 (MARK3), beclin 1 (BECN1) and telomerase protein component (TEP1), were selected from those that presented the highest different ratio of expression in adult Ph þ ALL resistant or sensitive to the tyrosine-kinase inhibitor STI571. 8 Using this approach, we analyzed bone marrow (BM) samples from 26 children (under 14 years of age) and nine adults with Ph þ ALL; BM-and PB-mononuclear cells (MNC) from eight and five healthy volunteers, respectively, were also studied.
The diagnosis of ALL Ph þ was based on morphological, cytochemical, immunophenotypic and molecular analysis. Children were treated according to the different consecutive protocols of the Associazione Italiana Ematologia Oncologia Pediatrica (AEIOP), whereas adult patients received protocols of the Northern Italy Leukemia Group (NILG). It is worth noting that two pediatric patients were identical twins (manuscript in preparation), and showed a different response to prednisone therapy. According to the BFM criteria, PGR was defined as the presence of less than 1000 lymphoblasts/ml blood after the first 7 days of prednisone therapy, and one intrathecal injection of ageadapted dose of MTX on day 1. Those with more than 1000 lymphoblasts/ml blood on day 8 were classified as prednisone poor responders (PPR).
BM and PB mononuclear cell preparations were obtained by Ficoll-Hypaque centrifugation, and contained more than 98% of leukemia blasts, as assessed by morphological evaluation. RNA was extracted from cryopreserved samples and from the cell line TOM1, by ultracentrifugation using CsCl gradient method. The cDNA reverse transcription was performed using 1,0 mg RNA and SuperscriptII enzyme (Invitrogen, Carlsbad, CA, USA) in 20 ml final volume. The resulting cDNA was subjected to qualitative or quantitative PCR. For the diagnosis of the t(9;22) translocation, we used qualitative single-round RT-PCR. In all cases positive for the BCR/ABL transcripts, amplification was confirmed on an independent aliquot of the BM aspirate.
Primers were designed using the primer design software Oligo 6.3 (National Biosciences, Inc., Plymonth, MN, USA), on the basis of gene sequences in the Ensembl Human Genome (http://www.ensembl.org). To avoid DNA crossamplification, primers were designed on different exons and tested on genomic DNA, with no amplification observed. The primer sequences were: b-GUS 5 To check for primer-dimers, melting curve analysis was performed at the end of each reaction, and no primer-dimers were observed. For relative quantification of gene expression, we first constructed standard curves for each gene by considering at least three points in triplicate, with serial dilution of the known starting copy number of the appropriate cDNA. The slopes of standard curves ranged from 2.9 to 3.7. Differences in the amount of total cDNA added to each reaction were normalized using the GUS genes as an endogenous control. A known quantity of the Ph þ positive cell line TOM1 (5 Â 10 3 cells) was used as a standard control. The normalized expression level of each sample was referred to the TOM1 normalized value for the same gene, which was arbitrarily assumed as value 1. Statistical comparison of each single gene expression in different subgroups was performed by a permutation t-test. A multidimensional permutation approach was adopted to simultaneously test the overall difference between subgroups, with regard to the nine genes together.
Compared to normal BM, the mean levels of gene expression in normal PB was very low, with exception of BECN1, which presented higher expression levels in PB, and HDAC2 and MAPKAPK3, which presented similar expression levels in BM and PB (Table 1) . Different patterns of gene expression were observed in normal BM when compared with Ph þ ALL blasts (Table 1) . For most genes (HDAC2, MAPKAPK3, CASP8, TEP1 and MCM6), the level of expression in normal BM was significantly higher than in affected patients' BM, both in children and adult, although a great heterogeneity was observed. Only for BECN1 and MARK3 genes, the opposite proved true, while for CCND2 the values were similar. The level of expression of CASP10 in normal BM was more similar to BM levels in childhood Ph þ ALL. This finding could suggest a possible participation of these genes in the Ph þ leukemogenesis. Further investigations are needed to evaluate whether this pattern of expression is exclusive to Ph þ ALL or whether it could be a more general mechanism of leukemogenesis. Overall, these differences, albeit statistically significant, should Correspondence be taken with caution due to the heterogeneity of BM-and PB-MNC, and the fact that BM-MNC cannot be considered the appropriate normal counterpart of BCR/ABL-positive leukemic cells.
The mean expression levels for each gene and their standard deviation (s.d.) were higher in Ph þ ALL children when compared to Ph þ ALL adults in 8/9 genes, suggesting a greater (but not statistically significant) variability in this group (Figure 1) . The analysis by a multidimensional test showed a statistically significant difference in expression levels of the nine genes between children and adult Ph þ ALL (P-value ¼ 0.001). In particular, a significant difference in expression levels was observed for the HDAC2, MAPKAPK3, CASP10, MARK3 and TEP1 genes ( Table 2 ). The highest difference was observed for CASP10. Interestingly, the pattern of expression of the adult group seems more similar to the PPR childhood group than to the PGR one ( Table 2 ). Whereas the PGR children presented four genes with P-value less than 0.05 (HDAC2, CASP10, TEP1 and MARK3) when compared with adults, these differences are reduced to two genes (CASP10 and TEP1) when comparing PPR children with adults.
Overall, no major differences were observed in gene expression profile for the selected genes between PGR and PPR pediatric patients (multidimensional P-value ¼ 0.4).
Interestingly, the CASP10 was the only gene that showed more than a two-fold change when comparing PGR with PPR pediatric patients ( Table 2 ). Although this is the higher observed difference, it is not statistically significant (P-value ¼ 0.06). Of note, within the PGR group, those patients who relapsed or were dead showed a level of expression more similar to PPR and adults, than to PGR children in complete continuous remission, more notably for MARK3, HDAC2 and CASP8 (data not shown). It is questionable whether these findings could predict different PGR subgroups, since treatment protocols (chemotherapy or BMT) and follow-up times were different in the analyzed patients.
The heterogeneous gene profile in Ph þ childhood ALL was confirmed and further reinforced by the analysis of expression of the selected genes in the twin pair with Ph þ ALL. Although both twins presented the same leukemia with a very short latency (manuscript in preparation), they had different responses to the prednisone therapy, and showed differences in gene expression profile, in particular for the HDAC2, CASP8, CCND2 and MARK3 genes (Figure 2) .
In summary, the panel of selected genes whose expression is significantly different in normal BM and Ph þ ALL could suggest a possible participation of some of these genes in the Ph þ leukemogenic process. A significant difference in gene expression profile between adult and children Ph þ ALL was found, suggesting that childhood Ph þ ALL is a heterogeneous disease also at biological level. However, no distinct pattern within childhood Ph þ ALL was identified according to steroid response. Due to the complexity and heterogeneity of Ph þ Table 2 Mean gene expression ratio and P-values between children (PGR and PPR) and adult Ph+ ALL 
We read with great interest the article by Rajkumar et al 1 on the effects of thalidomide in early-stage asymptomatic multiple myeloma. The authors propose that thalidomide may act by suppressing an angiogenic switch, thereby preventing progression of disease.
Another possible effect by which thalidomide may be acting in the early-stage disease is by anti-inflammatory effect. There is much suggestive evidence that inflammation is involved in the progression of plasma cell dyscrasia in the animal model, and that anti-inflammatory agents such as aspirin and celecoxib can inhibit disease progression. 2, 3 In humans, multiple myeloma is often associated with high CRP, il-6, beta 2 microglobulin, hypercoagulability, 4 and response to steroids, all suggesting chronic ongoing inflammation.
Thalidomide has potent anti-inflammatory effects through inhibition of tumor necrosis factor, suppression of NF kappa B activation in response to inflammatory agents, and downregulation of cell adhesion molecules LFA-l and ICAM-l. 5, 6 We wonder if the investigators have information about the effects of thalidomide on inflammatory markers in their patients, and if changes in inflammation corresponded to tumor response.
If the actions of thalidomide are through anti-inflammatory mechanisms, then other anti-inflammatory agents could be considered as adjunctive or alternative agents to prevent progression of asymptomatic to symptomatic disease. Ongoing studies to determine if celecoxib can achieve such an effect through anti-inflammatory mechanisms are ongoing at the Cleveland Clinic, Mayo Clinic, and the University of Arkansas. 
